Since the profibrotic effects of serotonin fibroblast growth and fibrogenesis are mediated via the 5-HT1A/B and 5-HT2A/B receptors, relevant drugs acting on these receptors should be potential treatments for CS-associated fibrotic complications [62]. This evidence concerns the gene HTR1A and Cowden syndrome 1.